Kalbe Farma Tbk PTKLBF:JKT

1,340
5.00 / 0.37 %
34.23m
26.58 %
0.872
Close in IDRToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of May 04 2016 10:14 BST.

Consensus recommendation

As of May 02, 2016, the consensus forecast amongst 22 polled investment analysts covering Kalbe Farma Tbk PT advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts deteriorated on May 02, 2016. The previous consensus forecast advised that Kalbe Farma Tbk PT would outperform the market.

Previous recommendations
Last year3 months ago2 months ago4 weeks agoLatest
Mouseover chart recommendation details.
Latest recommendation
Buy4
Outperform6
Hold8
Underperform4
Sell0
No opinion0

Share price forecast

The 21 analysts offering 12 month price targets for Kalbe Farma Tbk PT have a median target of 1,400, with a high estimate of 2,000 and a low estimate of 1,190. The median estimate represents a 4.48% increase from the last price of 1,340. View Full Financials

High+49.3 %2,000
Med+4.5 %1,400
Low-11.2 %1,190

Dividends

Historical dividend information is not available for Kalbe Farma Tbk PT. View Full Financials

Div growth (TTM)--
  • Mouseover chart for details.
  • Dividend forecast
  • Quarter 1
  • Quarter 2
  • Quarter 3
  • Quarter 4

Earnings history & estimates

On Apr 29, 2016, Kalbe Farma Tbk PT reported 1st quarter 2016 earnings of 12.02 per share.
The next earnings announcement is expected on Jul 29, 2016. View Full Interim Financials

Average growth rate+6.22 %

Kalbe Farma Tbk PT reported annual 2015 earnings of 42.76 per share on Feb 26, 2016. View Full Annual Financials

Average growth rate+8.10 %
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement

Revenue

PT. Kalbe Farma Tbk. had 1st quarter 2016 revenues of 4.55bn. This missed the 4.64bn consensus estimate of the 2 analysts following the company. This was 7.14% above the prior year's 1st quarter results. View Full Interim Financials

Average growth rate+1.86 %

PT. Kalbe Farma Tbk. had revenues for the full year 2015 of 17.89bn. This was 2.99% above the prior year's results. View Full Annual Financials

Average growth rate+13.46 %
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.